Landsburg DJ, Nasta SD, Gerson JN, Svoboda J, et al. Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy. Leuk Lymphoma 2021 Aug 26:1-4. doi: 10.1080/10428194.2021.1971224.
PMID: 34435548